Form 4: Marimed CEO Levine Reports Equity Transactions

Marimed Inc. CEO Jon R. Levine disclosed routine transactions involving the vesting of restricted stock units and subsequent share disposals for tax purposes.

Summary

• Jon R. Levine, President and CEO, Director, and 10% Owner of Marimed Inc. (MRMD), reported transactions on October 2, 2025.
• Acquired 11,517 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Disposed of 3,381 shares of common stock to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.161 per share.
• Following these transactions, direct beneficial ownership stands at 20,855,370 shares.
• Indirect beneficial ownership through the Jon Levine Family Trust is 6,684,640 shares.
• Remaining 34,552 Restricted Stock Units (RSUs) will vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027.

Sentiment

Score: 7

Explanation: The filing indicates a routine vesting of executive compensation (RSUs), which is a positive sign for management retention and alignment of interests, despite the standard tax-related share disposal. It reflects normal course of business for executive equity.

Positives

• CEO Jon R. Levine's Restricted Stock Units (RSUs) vested, indicating continued compensation and alignment of management interests with shareholder value.

Negatives

• A portion of the vested shares (3,381 shares) was disposed of to cover tax withholding obligations, which is a standard practice upon RSU vesting.

Future Outlook

Remaining Restricted Stock Units (RSUs) are scheduled to vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities [held by the Jon Levine Family Trust], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing reflects routine executive compensation and share ownership disclosure, common across all publicly traded companies, and does not provide specific insights into broader industry trends for Marimed Inc.

Related Party Transactions

• Indirect beneficial ownership of 6,684,640 shares is held by the Jon Levine Family Trust, for which the reporting person disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion, but also indicates continued executive alignment with company performance.
• Management: Receipt of vested equity compensation, reinforcing long-term incentives.

Next Steps

• Remaining Restricted Stock Units (RSUs) will vest in three equal installments on April 2, 2026, October 2, 2026, and April 2, 2027.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax withholding). It does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing confirms ongoing executive equity participation without introducing new catalysts for significant price movement.

Keywords

Marimed, MRMD, Jon R. Levine, Form 4, insider trading, stock transactions, RSU, restricted stock units, CEO, director, 10% owner